Systematic and pairwise analysis of the effects of aromatic halogenation and trifluoromethyl substitution on human liver microsomal clearance

Drug Metabolism Letters

Volumn 5, Issue 4, 2011, Pages 232-242

  Sun, Hao ^a   Keefer, Christopher E ^a   Scott, Dennis O ^a  

^a PFIZER INC   (United States)

Author keywords

Cytochrome p450; Drug design; Drug metabolism; Halogenation; Microsomal clearance; Pairwise analysis

Indexed keywords

AMFEBUTAMONE; AMLODIPINE; AMLODIPINE BESYLATE; ATORVASTATIN; AZELASTINE; BACLOFEN; CETIRIZINE; CITALOPRAM; CLOPIDOGREL; CLOTRIMAZOLE; DONEPEZIL; ESCITALOPRAM; EZETIMIBE; FENOFIBRATE; FLUOXETINE; FLUPHENAZINE; FUROSEMIDE; HYDROXYZINE; INDOMETACIN; MECLOZINE; MIDAZOLAM; PAROXETINE; PHENOTHIAZINE DERIVATIVE; ROSUVASTATIN; SERTRALINE; SITAGLIPTIN; TRAZODONE; TRIFLUOPERAZINE; TRIFLUOROPROMAZINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AROMATIC HALOGENATION; ARTICLE; CHLORINATION; DRUG CLEARANCE; DRUG DESIGN; DRUG METABOLISM; DRUG STRUCTURE; FLUORINATION; HALOGENATION; HUMAN; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

EID: 84855216769     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231211798472575     Document Type: Article

References (25)

1. Park, B. K.; Kitteringham, N. R.; O'Neill, P. M. Metabolism of fluorine-containing drugs. Annu. Rev. Pharmacol. Toxicol., 2001, 41, 443-70.
2. Berkowitz, D. B.; Karukurichi, K. R.; de la Salud-Bea, R.; Nelson, D. L.; McCune, C. D., Use of Fluorinated Functionality in Enzyme Inhibitor Development: Mechanistic and Analytical Advantages. J. Fluor. Chem., 2008, 129 (9), 731-742.
3. Dimagno, S. G.; Sun, H. The strength of weak interactions: aromatic fluorine in drug design. Curr. Top. Med. Chem., 2006, 6 (14), 1473-1482.
4. Schlosser, M. CF(3)-bearing aromatic and heterocyclic building blocks. Angew Chem Int Ed Engl., 2006, 45 (33), 5432-5446.
5. Vincent, S. H.; Reed, J. R.; Bergman, A. J.; Elmore, C. S.; Zhu, B.; Xu, S.; Ebel, D.; Larson, P.; Zeng, W.; Chen, L.; Dilzer, S.; Lasseter, K.; Gottesdiener, K.; Wagner, J. A.; Herman, G. A. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans. Drug Metab. Dispos., 2007, 35 (4), 533-538.
6. Ortiz de Montellano, P. R.; De Voss, J. J. Substrate Oxidation by Cytochrome P450 Enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry 3ed.; Ortiz de Montellano, P. R., Ed. Kluwer Academic / Plenum Publishers: New York, 2005.
7. Rosenblum, S. B.; Huynh, T.; Afonso, A.; Davis, H. R., Jr.; Yumibe, N.; Clader, J. W.; Burnett, D. A. Discovery of 1-(4- fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)- (4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption. J. Med. Chem., 1998, 41 (6), 973-980.
8. Keefer, C. E.; Chang, G.; Kauffman, G. W. Extraction of tacit knowledge from large ADME data sets via pairwise analysis. Bioorg. Med. Chem., 2011, 19 (12), 3739-3749.
9. R. S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos., 1999, 27 (11), 1350-1359.
10. Human Pooled Liver Microsomes, S9, and Cytosol, Becton, Dickinson and Company. http://www.bdbiosciences.com.
11. Sun, H.; Moore, C.; Dansette, P. M.; Kumar, S.; Halpert, J. R.; Yost, G. S. Dehydrogenation of the indoline-containing drug 4- chloro-N-(2-methyl-1-indolinyl)-3-sulfamoylbenzamide (indapamide) by CYP3A4: correlation with in silico predictions. Drug Metab. Dispos., 2009, 37 (3), 672-684.
12. Sun, H.; Yost, G. S. Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4. Chem. Res. Toxicol., 2008, 21 (2), 374-385.
13. Sun, H.; Sharma, R.; Bauman, J.; Walker, D. P.; Aspnes, G. E.; Zawistoski, M. P.; Kalgutkar, A. S. Differences in CYP3A4 catalyzed bioactivation of 5-aminooxindole and 5-aminobenzsultam scaffolds in proline-rich tyrosine kinase 2 (PYK2) inhibitors: retrospective analysis by CYP3A4 molecular docking, quantum chemical calculations and glutathione adduct detection using linear ion trap/orbitrap mass spectrometry. Bioorg. Med. Chem. Lett., 2009, 19 (12), 3177-3182.
14. Sun, H.; Scott, D. O. Metabolism of 4-aminopiperidine drugs by cytochrome P450s: molecular and quantum mechanical insights into drug design. ACS Med. Chem. Lett., 2011, 2(8), 638-643.
15. Thompson, T. N. Optimization of metabolic stability as a goal of modern drug design. Med. Res. Rev., 2001, 21 (5), 412-449.
16. Lewis, M. L.; Cucurull-Sanchez, L. Structural pairwise comparisons of HLM stability of phenyl derivatives: Introduction of the Pfizer metabolism index (PMI) and metabolism-lipophilicity efficiency (MLE). J. Comput. Aided Mol. Des., 2009, 23 (2), 97-103.
17. Matilde Marques, M.; Gamboa da Costa, G.; Blankenship, L. R.; Culp, S. J.; Beland, F. A. The effect of deuterium and fluorine substitution upon the mutagenicity of N-hydroxy-2,6- dimethylaniline. Mutat. Res., 2002, 506-507, 41-48.
18. Kellner-Weibel, G. L.; Nyarko, A. K.; Tchao, R.; Henesey, C. M.; Harvison, P. J. The effect of aromatic fluorine substitution on the nephrotoxicity and metabolism of N-(3,5- dichlorophenyl) succinimide in Fischer 344 rats. Toxicology, 1997, 117 (1), 73-83.
19. Bayburt, T. H.; Sligar, S. G. Single-molecule height measurements on microsomal cytochrome P450 in nanometer-scale phospholipid bilayer disks. Proc.Natl. Acad. Sci. U S A, 2002, 99 (10), 6725-6730.
20. Sun, H.; Scott, D. O. Structure-based drug metabolism predictions for drug design. Chem. Biol. Drug Des., 2010, 75 (1), 3-17.
21. Mandrioli, R.; Forti, G. C.; Raggi, M. A. Fluoxetine metabolism and pharmacological interactions: the role of cytochrome p450. Curr. Drug Metab., 2006, 7 (2), 127-133.
22. Ring, B. J.; Gillespie, J. S.; Eckstein, J. A.; Wrighton, S. A. Identification of the human cytochromes P450 responsible for atomoxetine metabolism. Drug Metab. Dispos., 2002, 30 (3), 319-323.
23. Tiseo, P. J.; Perdomo, C. A.; Friedhoff, L. T. Metabolism and elimination of 14C-donepezil in healthy volunteers: a single-dose study. Br. J. Clin. Pharmacol., 1998, 46 Suppl 1, 19-24.
24. Halpin, R. A.; Porras, A. G.; Geer, L. A.; Davis, M. R.; Cui, D.; Doss, G. A.; Woolf, E.; Musson, D.; Matthews, C.; Mazenko, R.; Schwartz, J. I.; Lasseter, K. C.; Vyas, K. P.; Baillie, T. A. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab. Dispos., 2002, 30 (6), 684-693.
25. Kalgutkar, A. S.; Griffith, D. A.; Ryder, T.; Sun, H.; Miao, Z.; Bauman, J. N.; Didiuk, M. T.; Frederick, K. S.; Zhao, S. X.; Prakash, C.; Soglia, J. R.; Bagley, S. W.; Bechle, B. M.; Kelley, R. M.; Dirico, K.; Zawistoski, M.; Li, J.; Oliver, R.; Guzman-Perez, A.; Liu, K. K.; Walker, D. P.; Benbow, J. W.; Morris, J. Discovery tactics to mitigate toxicity risks due to reactive metabolite formation with 2-(2-hydroxyaryl)-5-(trifluoromethyl)pyrido[4,3- d]pyrimidin-4(3h)-one derivatives, potent calcium-sensing receptor antagonists and clinical candidate(s) for the treatment of osteoporosis. Chem. Res. Toxicol., 2010, 23 (6), 1115-1126.